Ipca Labs enters into technology transfer agreement with Omexa Formulary

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-03-29 09:53 GMT   |   Update On 2024-03-29 09:57 GMT
Advertisement

Mumbai: lpca Laboratories Ltd. has entered into a Technology Transfer Agreement with Omexa Formulary Pvt. Ltd. for a biosimilar clone, process development and knowledge transfer for the global market.

Under this Agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market a anti-cancer biosimilar for global market.

This Agreement shall enable Omexa to develop this anti-cancer biosimilar from early stage of development to clinical trials and subsequent commercial launch. This agreement will also strengthen Omexa's capability of biosimilar development.

Advertisement

Commenting on this Agreement, Pranay Godha, Managing Director and CEO, lpca Laboratories said, "This collaboration with Omexa Formulary, an innovation driven and fast-growing biotech company, shall facilitate Omexa to build a solid foundation for potential anti-cancer and anti-inflammatory monoclonal antibody product development. This collaboration with Omexa in turn shall also help lpca in the development and delivery of affordable and quality biologic medication for the treatment of chronic illnesses in the global market - a presently unmet and crucial clinical need. lpca is committed to successfully develop quality and affordable biosimilars meeting global standards and gain a decisive edge in the battle against chronic ailments."

Commenting on this Agreement Dr. Nate Ramanathan, Managing Director & CEO of Omexa Formulary said, "This collaboration with lpca, a most reliable and trusted pharmaceutical company shall facilitate Omexa the availability of expertise and technology for the biosimilars development work and ensuring that Omexa play its part in serving our core values of affordable access to quality biologic drugs for a large population through our pioneering methods in R&D and manufacturing development.

Established in 1949, lpca is a pharmaceutical company. lpca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients. For more than 70 years, lpca has been a crucial healthcare partner in over 120 countries across the globe. lpca markets its branded formulations in India and rest of the world markets and generic formulations in United States, Europe, United Kingdom, Canada, Australia & New Zealand. APls manufactured by lpca are marketed across the globe. lpca has leading brands in pain, rheumatology, anti-malarials and hair care therapy and 5 of its brands rank amongst the top 300 brands (IQVIA December 2023).

Read also: Hitesh Kumar Maheshwari joins Ipca Labs as President - RnD (Formulations)

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News